GlobeNewswire

LM Industries Brings Manufacturing Into the Future as World's First Digital OEM

Dela

The creators of autonomous shuttle Olli form LM Industries, a company designing and building future-looking products with partners like Allianz, Airbus and the United States Marine Corps

SAN FRANCISCO, June 20, 2018 (GLOBE NEWSWIRE) -- Today, the creators of the Rally Fighter and Olli announced the formation of LM Industries Group, Inc., a technology-enabled manufacturer focused on mobility products headquartered in San Francisco. LM Industries is the world's first digital OEM - which can take concepts to deployed products in under one year, all on its unique digital thread. It brings products to market in an entirely new way, designing with its global community of experts, and applying technology such as 3D printing to create and assemble products in small batches at agile microfactories. The process challenges the century-long dependency on mass manufacturing which has failed to keep up with the modern pace of technological innovation.

LM Industries creates transportation, accessibility and mobility products with customers such as Allianz Group, Airbus and the United States Marine Corps, by combining co-creation, technology, and microfactories into one modern manufacturing process that builds high-quality, low-volume products at unprecedented speeds. Its efficiency allows products to be upgradeable like software - iterated regularly and fluidly to match rapidly changing consumer preferences. Bringing Launch Forth's design and Local Motor's microfactories into one parent company provides clients with a better alternative to mass manufacturing that gets the right products into the right people's hands at the right time. With shared resources and capabilities, LM Industries will explore more ambitious and ground-breaking projects to solve the most pressing issues of our time.

"Mass manufacturing is a relic of a past era. We're in the middle of a mobility revolt where current modes of transportation are not sustainable and do not match up with rapidly changing consumer preferences," said LM Industries CEO and co-founder John B. Rogers, Jr. "We can't keep producing products the same way we've been accustomed to. The world is moving too fast for traditional manufacturing to keep up. LM Industries is on a mission to transform mass manufacturing to micro-manufacturing in order to match the new pace of technology and quickly changing consumer needs."

Allianz is partnering with Local Motors to deploy Olli in multiple cities in order to help accelerate the understanding of insurance in our shared, autonomous world. The global insurer is also designing new mobility solutions and imagining the future of mobility insurance with Launch Forth. Now Jean-Marc Pailhol, Head of Global Market Management & Distribution at Allianz SE,  joins the LM Industries board to help guide future product development and encourage strategic global partnerships.

"Because they will be pushed by pollution and traffic constraints, the large cities will be the first to accept and implement the disruptive mobility products such as autonomous or flying vehicles for public transportation. LM Industries checks all the boxes with its product features: 100% electric, 100% autonomous, 100% connected and 90% 3D printed with the ability to produce in micro factories near bigger cities," said Pailhol. "In the future, a large part of the mobility market will be taken by small factories making solutions near the cities in which they are needed. LM Industries has a real competitive advantage in that they are a step ahead of the other AV manufacturers and have a real value proposition with their microfactories.  When I met Jay Rogers nearly two years ago, I quickly recognized the relevance of his value proposition from co-creation to micro-manufacturing to mobility solutions like Olli."

The latest project from Allianz and LM Industries is an accessibility device that can be customized to match any activity level or style choices. For the past 150 years, the design of the wheelchair has remained fundamentally the same, with the same benefits and many of the same problems. With limited upgradability and the stigma of a medical device, it is time for a major shift in mass mobility that is inclusively designed with accessibility in mind, but that is also functional and fun for all people.

Other in-progress projects include a modular logistics vehicle and an unmanned cargo system with the United States Marine Corps. The success of this effort shows the elasticity and nimbleness of LM Industries to provide on-target solutions in both the commercial and military sectors. If this project continues to achieve results ahead of schedule, it stands to augment the US military with a much needed responsive capability for vehicle systems development.

"LM Industries has proven to be an agile, adaptive, and innovative partner in maturing our hybrid logistics vision," said Lieutenant General Michael G. Dana, Deputy Commandant for Installation and Logistics. "Through the Launch Forth initiative, we are developing critically needed logistical capabilities for 21st century expeditionary operations. By leveraging the power of co-creation, we will rapidly develop time sensitive, demand-driven capabilities for our Marines."

"As we have proven with Olli and other products, we can change designs based on consumer preferences in a day and custom-develop a fleet of large machines in a matter of weeks," said Rogers. "Our vision goes far beyond ground mobility; our manufacturing process can be applied to virtually any hardware product, from aviation to infrastructure, housing and other large industrial products. If Amazon created a new eco-system to monetize the long-tail of ordering things, LM Industries has created an ecosystem to monetize the long-tail of making things. Ecosystem shifts like this come once in a century."

About LM Industries
LM Industries exists to shape the future for the better. We make technology forward products using the four pillars of our innovation ecosystem: co-creation, microfactories, direct digital manufacturing, lab partnerships. We begin every product with community-powered, human-centered design and by reinventing manufacturing with microfactories, we create big things on a smaller scale for the local communities that actually need them. Our process breaks down the barriers to sustainable product development - reducing waste, consuming less energy, and ensuring we use only the materials we need. We have the unrivaled capacity to make the improbable come to life. Based in San Francisco, LM Industries is the parent company of Local Motors and Launch Forth.

Media Contact
LaunchSquad for LM Industries
lmi@launchsquad.com
415.625.8555




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LM Industries via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum